Indivior PLC

Report Publication Announcement • Nov 20, 2023

National Storage Mechanism | Additional information

RNS Number : 0290U

Indivior PLC

20 November 2023

Indivior To Participate in Jefferies Investor Event on November 21st

Slough, UK, and Richmond, VA, November 20, 2023 - Indivior PLC (LSE/NASDAQ: INDV) today announced that it will participate in the following investor event:

·    Jefferies Investor Event (Indivior CEO Fireside Chat) - Virtual

Mark Crossley, Chief Executive Officer, will participate in a fireside chat at 9:00 a.m. US Eastern Time on November 21st.  The fireside chat will be publicly available and can be accessed using the following weblink:

Webcast link

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-402-7123 or jason.thompson@indivior.com

Tim Owens

Director, Investor Relations

Tel: 804-263-3978 or timothy.owens@indivior.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCNKKBPQBDDBDB